Lawrence Fong, MD
Professor
Medicine
School of Medicine

He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. Dr. Fong’s research examines the determinants of clinical response and resistance to immunotherapies.

• PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways.
  Cancer immunology research 2024 Yang J, Wang L, Byrnes JR, Kirkemo LL, Driks H, Belair CD, Aguilar OA, Lanier LL, Wells JA, Fong L, Blelloch R
• Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
  Cancer immunology research 2024 Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, …
• Outcomes of high-grade immune checkpoint inhibitor hepatitis in hospitalized and non-hospitalized patients.
  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024 Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Zucker SD, Grover S
• Immune modulation with RANKL blockade through denosumab treatment in patients with cancer.
  Cancer immunology research 2024 Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L
• Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.
  Clinical genitourinary cancer 2023 Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP
• TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments.
  Immunity 2023 Tsai YL, Arias-Badia M, Kadlecek TA, Lwin YM, Srinath A, Shah NH, Wang ZE, Barber D, Kuriyan J, Fong L, Weiss A
• The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies.
  Journal of the National Cancer Institute 2023 Annapragada A, Sikora AG, Marathe H, Liu S, Demetriou M, Fong L, Gao J, Kufe D, Morris ZS, Vilar E, Sharon E, Hutson A, Odunsi K
• Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
  The Lancet. Oncology 2023 Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong…
• CD4+ T cells help myeloid-mediated killing of immune-evasive tumors.
  Trends in cancer 2023 Wu K, Fong L
• Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
  Nature medicine 2023 Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R…
• Tumor cell heterogeneity drives spatial organization of the intratumoral immune response in squamous cell skin carcinoma.
  bioRxiv : the preprint server for biology 2023 Tanaka M, Lum L, Hu K, Ledezma-Soto C, Samad B, Superville D, Ng K, Adams Z, Kersten K, Fong L, Combes AJ, Krummel M, Reeves M
• Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis.
  Journal of the National Comprehensive Cancer Network : JNCCN 2023 Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Grover S, Zucker SD
• Vaccinating against cancer: getting to prime time.
  Journal for immunotherapy of cancer 2023 Chang R, Gulley JL, Fong L
• Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
  British journal of cancer 2023 Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
  bioRxiv : the preprint server for biology 2023 Conway JR, Tewari AK, Camp SY, Han S, Crowdis J, He MX, Nyame YA, AlDubayan SH, Schultz N, Szallasi Z, Pomerantz MM, Freedman ML, Fong L, Nelson PS, Brown M, Salari K, Allen EV
• Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
  Cell 2023 Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo…
• Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
  Journal for immunotherapy of cancer 2023 Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C,…
• Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
  Urologic oncology 2022 Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ
• The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Cancer research 2022 Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, …
• Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis.
  Cell reports 2022 Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L
• Agonizing over the Stimulatory Immune Checkpoint ICOS.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Lee JC, Fong L
• Editorial: Advancements in immunology and immunotherapy for breast cancer.
  Frontiers in oncology 2022 Sugie T, Salgado R, Fong L
• Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer.
  Science immunology 2022 Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z
• ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
  The oncologist 2022 Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, Vangala S, Gutierrez AA, Haas NB
• Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Culine S, …
• Effect of Early Infant Probiotic Supplementation on Eczema, Asthma, and Rhinitis at 7 Years of Age.
  Pediatrics 2022 Cabana MD, LeCroy MN, Menard-Livingston A, Rodgers CRR, McKean M, Caughey AB, Fong L, Lynch S, Wong A, Leong R, Boushey HA, Hilton JF
• A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R
• Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus.
  Science (New York, N.Y.) 2022 Perez RK, Gordon MG, Subramaniam M, Kim MC, Hartoularos GC, Targ S, Sun Y, Ogorodnikov A, Bueno R, Lu A, Thompson M, Rappoport N, Dahl A, Lanata CM, Matloubian M, Maliskova L, Kwek SS, Li T, Slyper M,…
• APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
  Frontiers in oncology 2022 Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J,…
• Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
  Journal for immunotherapy of cancer 2022 Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ
• Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox.
  Immunity 2021 Oh DY, Fong L
• Toward a better understanding of T cells in cancer.
  Cancer cell 2021 Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O
• In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET.
  ACS central science 2021 Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS
• IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
  Journal for immunotherapy of cancer 2021 Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser …
• A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.
  Urologic oncology 2021 Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, …
• Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.
  Prostate cancer and prostatic diseases 2021 Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Lauer P, Brockstedt D, Patricia D, Wade M, Zudaire E, Bandyopadhyay N, Parasrampuria DA, Girgis S, Mason GE, Knoblauch RE, …
• A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Fong L, Morris MJ, Sartor O, Higano CS, Pagliaro L, Alva A, Appleman LJ, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel EE, Yuen KC, Datye A, Armstrong AJ, Petrylak DP
• Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
  Journal for immunotherapy of cancer 2021 Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, …
• Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
  Journal for immunotherapy of cancer 2021 Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, …
• Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
  Journal for immunotherapy of cancer 2021 Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L
• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
  Cancer immunology, immunotherapy : CII 2021 Wustrack RL, Shao E, Sheridan J, Zimel M, Cho SJ, Horvai AE, Luong D, Kwek SS, Fong L, Okimoto RA
• How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
  Prostate cancer and prostatic diseases 2021 Stultz J, Fong L
• Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy.
  Journal of immunological methods 2021 Zhang L, Cham J, Cooley J, He T, Hagihara K, Yang H, Fan F, Cheung A, Thompson D, Kerns BJ, Fong L
• Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
  European urology 2021 Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, …
• Transcriptional mediators of treatment resistance in lethal prostate cancer.
  Nature medicine 2021 He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z,…
• Non-radioactive and sensitive tracking of neutrophils towards inflammation using antibody functionalized magnetic particle imaging tracers.
  Nanotheranostics 2021 Chandrasekharan P, Fung KLB, Zhou XY, Cui W, Colson C, Mai D, Jeffris K, Huynh Q, Saayujya C, Kabuli L, Fellows B, Lu Y, Yu E, Tay ZW, Zheng B, Fong L, Conolly SM
• Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
  Molecular pharmaceutics 2021 Levy ES, Chang R, Zamecnik CR, Dhariwala MO, Fong L, Desai TA
• Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D…
• Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
  Journal for immunotherapy of cancer 2021 Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR…
• Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
  Cancer immunology, immunotherapy : CII 2021 Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L
• Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas.
  Cancer discovery 2021 Keenan BP, Fong L
• Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.
  Cancer immunology research 2020 Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L
• An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
  Molecular imaging and biology 2020 Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ
• Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.
  Frontiers in oncology 2020 Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM
• Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
  Molecular therapy : the journal of the American Society of Gene Therapy 2020 Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL
• The DNA methylation landscape of advanced prostate cancer.
  Nature genetics 2020 Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, …
• Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
  Journal for immunotherapy of cancer 2020 Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, …
• Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
  Journal of the National Cancer Institute 2020 Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL
• Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino…
• Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
  Journal for immunotherapy of cancer 2020 Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L
• Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
  BJU international 2020 Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis …
• Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020 de Almeida DVP, Fong L, Rettig MB, Autio KA
• Tissue Determinants of Human NK Cell Development, Function, and Residence.
  Cell 2020 Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL
• Immune Checkpoint Inhibition in Prostate Cancer.
  Trends in cancer 2020 Nicholson LT, Fong L
• Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, …
• TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.
  Frontiers in immunology 2020 Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L
• Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.
  Cancer immunology research 2019 Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L
• Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
  JCO precision oncology 2019 Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E
• Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, Liu G
• Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
  Journal for immunotherapy of cancer 2019 Keenan BP, Fong L, Kelley RK
• Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
  JAMA oncology 2019 Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M,…
• Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de …
• Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
  Cell 2019 Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Blelloch R
• The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
  Journal of the National Cancer Institute 2019 Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, …
• Immunity in the Time of Metastases.
  Immunity 2018 Oh DY, Fong L
• Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
  The Journal of clinical investigation 2018 Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, …
• Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
  Nature medicine 2018 McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, …
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.
  Oncoimmunology 2018 Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L
• A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4.
  Bioconjugate chemistry 2018 Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ
• Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
  Clinical genitourinary cancer 2018 Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
  Cell reports 2018 Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M
• Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
  Nature medicine 2018 McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, …
• Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies.
  Oncology (Williston Park, N.Y.) 2018 Patel A, Fong L
• Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin …
• Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
  Oncology (Williston Park, N.Y.) 2018 Patel A, Fong L
• Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.
  Oncoimmunology 2018 Cha E, Fong L
• A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
  The oncologist 2018 Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ
• TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
  Nature 2018 Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Senbabaoglu Y, Santoro …
• Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells.
  Oncotarget 2017 Sun Z, Wang CY, Lawson DA, Kwek S, Velozo HG, Owyong M, Lai MD, Fong L, Wilson M, Su H, Werb Z, Cooke DL
• Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
  Clinical genitourinary cancer 2017 Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L
• Imaging PD-L1 Expression with ImmunoPET.
  Bioconjugate chemistry 2017 Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI…
• Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
  JCI insight 2017 Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA
• Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial.
  Pediatrics 2017 Cabana MD, McKean M, Caughey AB, Fong L, Lynch S, Wong A, Leong R, Boushey HA, Hilton JF
• High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
  Clinical genitourinary cancer 2017 Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R…
• 3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.
  BMC bioinformatics 2017 Zhang L, Cham J, Paciorek A, Trager J, Sheikh N, Fong L
• Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
  The New England journal of medicine 2017 Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, …
• Systemic Immunity Is Required for Effective Cancer Immunotherapy.
  Cell 2017 Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG
• Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
  Cancer research 2016 Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
  Journal for immunotherapy of cancer 2016 McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL
• Television During Meals in the First 4 Years of Life.
  Clinical pediatrics 2016 Thimmig LM, Cabana MD, Bentz MG, Potocka K, Beck A, Fong L, Chao C, Caughey AB, Wong A, McKean M
• Can Prostate Cancer Really Respond to Immunotherapy?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Kim W, Fong L
• Immunotherapy in genitourinary malignancies.
  Current opinion in urology 2016 Wattenberg MM, Fong L, Madan RA, Gulley JL
• Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
  Cancer immunology research 2016 Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L
• Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.
  Cancer research 2016 Sheikh N, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager J, Fong L
• Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, …
• Prospects for the use of ipilimumab in treating advanced prostate cancer.
  Expert opinion on biological therapy 2016 Wei XX, Fong L, Small EJ
• GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
  Oncoimmunology 2015 Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE
• Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
  Expert review of vaccines 2015 Wei XX, Fong L, Small EJ
• On the Verge: Immunotherapy for Colorectal Carcinoma.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Oh DY, Venook AP, Fong L
• Transglutaminase 4 as a prostate autoantigen in male subfertility.
  Science translational medicine 2015 Landegren N, Sharon D, Shum AK, Khan IS, Fasano KJ, Hallgren Å, Kampf C, Freyhult E, Ardesjö-Lundgren B, Alimohammadi M, Rathsman S, Ludvigsson JF, Lundh D, Motrich R, Rivero V, Fong L, Giwercman A, …
• Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
  Cancer immunology research 2015 Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L
• A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND
• Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ
• Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
  Journal of the National Cancer Institute 2014 Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ
• Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL
• Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
  Science translational medicine 2014 Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L
• Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance.
  The Journal of experimental medicine 2014 Khan IS, Mouchess ML, Zhu ML, Conley B, Fasano KJ, Hou Y, Fong L, Su MA, Anderson MS
• The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Friedlander TW, Fong L
• Beyond sipuleucel-T: immune approaches to treating prostate cancer.
  Current treatment options in oncology 2014 Cheng ML, Fong L
• Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
  Urologic oncology 2014 Lou DY, Fong L
• Effects of RANKL-Targeted Therapy in Immunity and Cancer.
  Frontiers in oncology 2014 Cheng ML, Fong L
• Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
  Journal of immunology (Baltimore, Md. : 1950) 2012 Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L
• Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
  Nature reviews. Cancer 2012 Kwek SS, Cha E, Fong L
• A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.
  Oncology reports 2011 Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ
• Immunotherapy for prostate cancer: biology and therapeutic approaches.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Cha E, Fong L
• Interplay between CD8α+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses.
  PloS one 2011 Kapadia D, Sadikovic A, Vanloubbeeck Y, Brockstedt D, Fong L
• A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
  Cancer 2011 Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE
• Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
  Transplantation 2010 Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG
• Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients.
  Cancer research 2010 Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R
• Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
  Urologic oncology 2010 Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ
• Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB
• An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse.
  Journal of immunology (Baltimore, Md. : 1950) 2010 DeVoss JJ, LeClair NP, Hou Y, Grewal NK, Johannes KP, Lu W, Yang T, Meagher C, Fong L, Strauss EC, Anderson MS
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ
• HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
  Cancer immunology, immunotherapy : CII 2010 Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG
• Therapeutic vaccines for prostate cancer.
  Current opinion in molecular therapeutics 2010 Cha E, Fong L
• Developing immunotherapy as legitimate therapy for patients with prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Small EJ, Fong L
• Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance.
  Science translational medicine 2009 Shum AK, DeVoss J, Tan CL, Hou Y, Johannes K, O'Gorman CS, Jones KD, Sochett EB, Fong L, Anderson MS
• A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM
• An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.
  The Journal of clinical investigation 2009 Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L
• Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
  Cancer research 2009 Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ
• Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Fong L, Small EJ
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
  Blood 2008 Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L
• SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
  Proceedings of the National Academy of Sciences of the United States of America 2008 Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP
• Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen.
  Journal of immunology (Baltimore, Md. : 1950) 2008 Hou Y, Kavanagh B, Fong L
• Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
  The Journal of urology 2007 Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ
• Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2007 Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L
• Immunotherapy for prostate cancer.
  Current oncology reports 2007 Fong L, Small EJ
• A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP
• Spontaneous autoimmunity prevented by thymic expression of a single self-antigen.
  The Journal of experimental medicine 2006 DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi RR, Caspi R, Fong L, Anderson MS
• A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
  BJU international 2006 Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ
• Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
  Cancer 2006 Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ
• Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
  The Journal of urology 2006 Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ
• A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
  Molecular therapy : the journal of the American Society of Gene Therapy 2006 Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G
• Immunotherapy for prostate cancer.
  Current urology reports 2006 Fong L, Small EJ
• CTLA-4 blockade: autoimmunity as treatment.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Kapadia D, Fong L
• Immunotherapy for prostate cancer.
  Seminars in oncology 2003 Fong L, Small EJ
• Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.
  Clinical immunology (Orlando, Fla.) 2003 Engleman EG, Fong L
• Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation.
  Journal of virology 2002 Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG
• In vivo manipulation of dendritic cells to induce therapeutic immunity.
  Blood 2002 Merad M, Sugie T, Engleman EG, Fong L
• Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
  Journal of immunology (Baltimore, Md. : 1950) 2001 Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG
• Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
  Proceedings of the National Academy of Sciences of the United States of America 2001 Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG
• Dendritic cells injected via different routes induce immunity in cancer patients.
  Journal of immunology (Baltimore, Md. : 1950) 2001 Fong L, Brockstedt D, Benike C, Wu L, Engleman EG
• Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo.
  Blood 2000 Merad M, Fong L, Bogenberger J, Engleman EG
• Dendritic cells in cancer immunotherapy.
  Annual review of immunology 2000 Fong L, Engleman EG
• Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.
  Clinical immunology (Orlando, Fla.) 1999 Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
  Nature medicine 1999 Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM
• Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation.
  Transplantation 1998 Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S
• Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R
• Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide.
  Journal of immunology (Baltimore, Md. : 1950) 1997 Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB